Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, October 21, 2018

Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow

Memorize this so when you have a stroke you can point out what needs to be done. All because NO one in the whole stroke medical world is writing and distributing stroke protocols. You're screwed until we get some stroke leadership.

Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow

Annals of Neurology Tian DC, et al. | October 10, 2018

In acute ischemic stroke patients in a delayed time window, researchers tested the effectiveness of co-administration of fingolimod with alteplase. Study participants included those with an internal carotid artery or middle cerebral artery proximal occlusion within 4.5-6 hours from symptom onset. The results obtained from this prospective, randomized, open-label, blinded endpoint clinical trial indicated that fingolimod may enhance the effectiveness of alteplase administration in the 4.5- to 6-hour time window in those with a proximal cerebral arterial occlusion and salvageable penumbral tissue by promoting both anterograde reperfusion and retrograde collateral flow. Researchers noted that study participants who received fingolimod and alteplase showed a greater decline in the perfusion lesion accompanied by suppressed infarct growth by 24 hours.
Read the full article on Annals of Neurology

No comments:

Post a Comment